175 related articles for article (PubMed ID: 35045990)
1. Fluvoxamine for symptomatic outpatients with COVID-19.
Wu PE; Austin E; Leong D
CMAJ; 2022 Feb; 194(7):E258. PubMed ID: 35045990
[No Abstract] [Full Text] [Related]
2. Fluvoxamine for COVID-19?
Med Lett Drugs Ther; 2021 May; 63(1623):69-70. PubMed ID: 33976099
[No Abstract] [Full Text] [Related]
3. Complex movement disorder associated with fluvoxamine.
Bronner IM; Vanneste JA
Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160
[No Abstract] [Full Text] [Related]
4. Violent acts associated with fluvoxamine treatment.
Okada F; Okajima K
J Psychiatry Neurosci; 2001 Sep; 26(4):339-40. PubMed ID: 11590975
[No Abstract] [Full Text] [Related]
5. Citalopram and fluvoxamine in Tourette's disorder.
Bajo S; Battaglia M; Pegna C; Bellodi L
J Am Acad Child Adolesc Psychiatry; 1999 Mar; 38(3):230-1. PubMed ID: 10087681
[No Abstract] [Full Text] [Related]
6. Increased libido in a woman treated with fluvoxamine: a case report.
Hori H; Yoshimura R; Nakamura J
Acta Psychiatr Scand; 2001 Apr; 103(4):312-4. PubMed ID: 11328247
[TBL] [Abstract][Full Text] [Related]
7. Restlessness related to SSRI withdrawal.
Hirose S
Psychiatry Clin Neurosci; 2001 Feb; 55(1):79-80. PubMed ID: 11235863
[TBL] [Abstract][Full Text] [Related]
8. Childhood trichotillomania. Successful treatment with fluoxetine following an SSRI failure.
Palmer CJ; Yates WR; Trotter L
Psychosomatics; 1999; 40(6):526-8. PubMed ID: 10581985
[No Abstract] [Full Text] [Related]
9. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
[TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.
Facente SN; Reiersen AM; Lenze EJ; Boulware DR; Klausner JD
Drugs; 2021 Dec; 81(18):2081-2089. PubMed ID: 34851510
[TBL] [Abstract][Full Text] [Related]
11. Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.
Nafziger AN; Bertino JS; Goss-Bley AI; Kashuba AD
J Clin Psychiatry; 1999 Mar; 60(3):187-90. PubMed ID: 10192595
[TBL] [Abstract][Full Text] [Related]
12. Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports.
Chong SA; Tan CH; Lee HS
J Clin Psychopharmacol; 1997 Feb; 17(1):68-9. PubMed ID: 9004072
[No Abstract] [Full Text] [Related]
13. Serotonin syndrome and fluvoxamine: a case study.
Bastani JB; Troester MM; Bastani AJ
Nebr Med J; 1996 Apr; 81(4):107-9. PubMed ID: 8628448
[TBL] [Abstract][Full Text] [Related]
14. [Severe withdrawal symptoms with fever upon stopping paroxetine].
Bakker A
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1795; author reply 1795-6. PubMed ID: 10494333
[No Abstract] [Full Text] [Related]
15. A display of hypomania in a depressed male in response to fluvoxamine.
Horiguchi T; Sai S
World J Biol Psychiatry; 2001 Oct; 2(4):201-4. PubMed ID: 12587152
[TBL] [Abstract][Full Text] [Related]
16. Seizure possibly associated with fluvoxamine.
Kim KY; Craig JM; Hawley JM
Ann Pharmacother; 2000 Nov; 34(11):1276-8. PubMed ID: 11098342
[TBL] [Abstract][Full Text] [Related]
17. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
Silver H; Nassar A; Aharon N; Kaplan A
Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
[TBL] [Abstract][Full Text] [Related]
20. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?
Hoertel N
JAMA Netw Open; 2021 Nov; 4(11):e2136510. PubMed ID: 34779851
[No Abstract] [Full Text] [Related]
[Next] [New Search]
